Last reviewed · How we verify

Decompensated chronic heart failure — Treatment Landscape & Competitive Intelligence

Decompensated chronic heart failure (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Decompensated chronic heart failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Natrecor NESIRITIDE Scios Llc Natriuretic Peptide Atrial natriuretic peptide receptor 1 2001-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Scios Llc · 1 drug in Decompensated chronic heart failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Decompensated chronic heart failure:

Cite this brief

Drug Landscape (2026). Decompensated chronic heart failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/decompensated-chronic-heart-failure. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing